Skip to main content
Industry News
AZ, BioKangtai ink COVID-19 vaccine licensing deal

AstraZeneca and China's BioKangtai have entered into a licensing deal for AZ's COVID-19 vaccine candidate AZD1222, developed by the UK's University of Oxford, to supply the shots to China. The companies, which did not disclose the deal's financial terms, will also consider vaccine production for other countries, with AZ granting BioKangtai exclusive clinical development, manufacturing, and marketing rights in China.

Full Story: